Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Dolin

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Clinical Pharmacology and Therapeutics|May 1, 1991
Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complexC A Knupp, W C Shyu, R Dolin, et al.
Reviews of Infectious Diseases|July 1, 1990
2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complexR Dolin, J S Lambert, G D Morse, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1993
Longitudinal analysis of responses to oral didanosine therapy following zidovudine therapy in advanced infection with human immunodeficiency virusC McLaren, M Rozencweig, M Beltangady, et al.
Lancet (London, England)|May 5, 1979
A waterborne outbreak of gastroenteritis with secondary person-to-person spread. Association with a viral agentD M Morens, R M Zweighaft, T M Vernon, et al.
The Journal of Infectious Diseases|January 1, 1983
Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistanceA Z Kapikian, R G Wyatt, M M Levine, et al.
Blood|December 15, 1992
Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus diseaseL P Schacter, M Rozencweig, M Beltangady, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1992
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trialsG L Drusano, G J Yuen, G Morse, et al.
JAMA|August 10, 1994
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials NetworkR B Belshe, B S Graham, M C Keefer, et al.
The Journal of Infectious Diseases|December 1, 1993
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group NetworkR B Belshe, M L Clements, R Dolin, et al.
American Journal of Epidemiology|April 1, 1990
Foodborne Snow Mountain agent gastroenteritis with secondary person-to-person spread in a retirement communityS M Gordon, L S Oshiro, W R Jarvis, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Clinical Pharmacology and Therapeutics|May 1, 1991
Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complexC A Knupp, W C Shyu, R Dolin, et al.
Reviews of Infectious Diseases|July 1, 1990
2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complexR Dolin, J S Lambert, G D Morse, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1993
Longitudinal analysis of responses to oral didanosine therapy following zidovudine therapy in advanced infection with human immunodeficiency virusC McLaren, M Rozencweig, M Beltangady, et al.
Lancet (London, England)|May 5, 1979
A waterborne outbreak of gastroenteritis with secondary person-to-person spread. Association with a viral agentD M Morens, R M Zweighaft, T M Vernon, et al.
The Journal of Infectious Diseases|January 1, 1983
Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistanceA Z Kapikian, R G Wyatt, M M Levine, et al.
Blood|December 15, 1992
Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus diseaseL P Schacter, M Rozencweig, M Beltangady, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1992
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trialsG L Drusano, G J Yuen, G Morse, et al.
JAMA|August 10, 1994
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials NetworkR B Belshe, B S Graham, M C Keefer, et al.
The Journal of Infectious Diseases|December 1, 1993
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group NetworkR B Belshe, M L Clements, R Dolin, et al.
American Journal of Epidemiology|April 1, 1990
Foodborne Snow Mountain agent gastroenteritis with secondary person-to-person spread in a retirement communityS M Gordon, L S Oshiro, W R Jarvis, et al.
Pageof 11